WEBULL
News
PAVMZ
0.0009
-40.00%
-0.0006
PAVMED INC <PAVM.O>: ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $17 FROM $20
Reuters · 12/10 08:33
PAVmed Shareholders Approve Reverse Stock Split and Share Reduction
Reuters · 12/05 21:16
PAVMED INC - QTRLY SHR LOSS $0.29
Reuters · 11/12 22:36
PAVmed Inc. to Report Third Quarter 2025 Financial Results
Reuters · 10/30 12:03
Lucid Diagnostics Inc. Files Initial Beneficial Ownership Statement for Director John R. Palumbo
Reuters · 10/07 20:46
PAVmed Subsidiary Veris Health Launches Commercial Phase of Strategic Partnership with Ohio State University Comprehensive Cancer Center
Reuters · 10/07 12:03
PAVMED SUBSIDIARY, VERIS HEALTH AND THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER LAUNCH COMMERCIAL PHASE OF STRATEGIC PARTNERSHIP AGREEMENT
Reuters · 10/07 12:02
Lucid Diagnostics Inc. Files Prospectus Supplement for Common Stock Offering, Raising Approximately $26.9 Million
Reuters · 09/11 13:28
BUZZ-Lucid Diagnostics slides on $25 mln stock sale
Reuters · 09/10 12:29
Dennis Matheis, Director, Reports Acquisition of Common Shares in Lucid Diagnostics Inc
Reuters · 08/22 21:18
PAVmed Inc. Reports Q2 2025 Results: Revenue at $1.2 Million, GAAP Net Loss of $13.3 Million, EPS at $(0.74); Adjusted Loss at $1.8 Million, EPS at $(0.11)
Reuters · 08/14 12:03
Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters · 08/13 13:32
Lucid Diagnostics Inc. Reports Q2 2025 Revenue of $1.2 Million, Processing 2,756 EsoGuard Tests
Reuters · 08/13 12:01
PAVmed Inc <PAVM.OQ> expected to post a loss of 13 cents a share - Earnings Preview
Reuters · 08/11 20:03
Lucid Diagnostics Inc <LUCD.OQ> expected to post a loss of 12 cents a share - Earnings Preview
Reuters · 08/11 13:17
PAVmed Inc. Announces Upcoming Business Update Conference Call and Webcast
Reuters · 07/31 12:02
PAVmed Inc. Granted Additional 180 Days by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Reuters · 07/30 12:01
MOLDX TO CONVENE EXPERT MEDICAL PANEL ON MEDICARE LOCAL COVERAGE DETERMINATION (LCD) FOR LUCID DIAGNOSTICS' ESOGUARD® ESOPHAGEAL DNA TEST
Reuters · 07/16 11:31
PAVMED SUBSIDIARY VERIS HEALTH COMPLETES $2.5 MILLION DIRECT EQUITY FINANCING
Reuters · 06/24 12:01
MAJOR CALIFORNIA HEALTH SYSTEM LAUNCHES COMPREHENSIVE ESOPHAGEAL PRECANCER TESTING PROGRAM USING LUCID DIAGNOSTICS' ESOGUARD® ESOPHAGEAL DNA TEST
Reuters · 06/18 16:02
More
Webull provides a variety of real-time PAVMZ stock news. You can receive the latest news about Pavmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About PAVMZ
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.